GlassScriptPhysician profile
Drita Gojcaj
NPI 1891288932
$3,825.62
in general payments reported to CMS, 2019-2025
27 companies · $732 in 2025
The $732 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $623 · 2022: $823 · 2023: $931 · 2024: $716 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,379.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.30 | 2021-2025 | |
| Pfizer INC. | $581.14 | 2023-2025 | |
| Lilly USA, LLC | $568.36 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $342.82 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $207.75 | 2022-2025 | Otezla, Repatha, Evenity |
| Impel Pharmaceuticals INC. | $148.79 | 2023 | Trudhesa |
| Regeneron Healthcare Solutions, INC. | $140.28 | 2024 | Evkeeza |
| Exact Sciences Corporation | $103.62 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $96.19 | 2022 | |
| Currax Pharmaceuticals LLC | $78.63 | 2021-2022 | |
| Ibsa Pharma INC. | $71.26 | 2022-2025 | Tirosint, Licart, Flector |
| Nestle Healthcare Nutrition INC. | $66.41 | 2021-2022 | |
| Neos Therapeutics, LP | $62.06 | 2023-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Aimmune Therapeutics, INC. | $50.21 | 2024 | |
| Amarin Pharma, INC. | $45.94 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $37.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.52 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.85 | 2021-2024 | Xifaxan |
| Antares Pharma, INC. | $31.22 | 2024-2025 | Xyosted |
| Cranial Technologies, INC | $27.71 | 2022-2023 | Doc Band |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.74 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.47 | 2025 | Breztri |
| Evofem Biosciences, INC. | $20.05 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.76 | 2023 | Quviviq |
| Lundbeck LLC | $17.11 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $11.77 | 2022 | |
| Glaxosmithkline, LLC. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drita Gojcaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.